Assetmark Inc. Buys 19,844 Shares of Lantheus Holdings, Inc. $LNTH

Assetmark Inc. boosted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 20.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 118,503 shares of the medical equipment provider’s stock after acquiring an additional 19,844 shares during the quarter. Assetmark Inc.’s holdings in Lantheus were worth $6,078,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Stanley Laman Group Ltd. increased its position in Lantheus by 38.7% in the 3rd quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock valued at $4,087,000 after acquiring an additional 22,229 shares in the last quarter. American Assets Inc. acquired a new position in shares of Lantheus during the third quarter worth approximately $872,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Lantheus during the third quarter valued at approximately $2,184,000. Fox Run Management L.L.C. acquired a new stake in shares of Lantheus in the second quarter valued at approximately $654,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Lantheus in the third quarter valued at approximately $3,866,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Up 1.0%

Lantheus stock opened at $69.38 on Tuesday. The firm has a market capitalization of $4.60 billion, a price-to-earnings ratio of 29.15 and a beta of -0.08. The company’s 50 day simple moving average is $66.44 and its 200 day simple moving average is $59.37. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $111.29.

Analysts Set New Price Targets

LNTH has been the topic of a number of recent research reports. Truist Financial increased their price objective on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Finally, Mizuho raised their price target on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus price target of $78.00.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.